SUPPLEMENTARY INFORMATION Supplementary Methods
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Clinical Utility Gene Card For: 3-M Syndrome – Update 2013
European Journal of Human Genetics (2014) 22, doi:10.1038/ejhg.2013.156 & 2014 Macmillan Publishers Limited All rights reserved 1018-4813/14 www.nature.com/ejhg CLINICAL UTILITY GENE CARD UPDATE Clinical utility gene card for: 3-M syndrome – Update 2013 Muriel Holder-Espinasse*,1, Melita Irving1 and Vale´rie Cormier-Daire2 European Journal of Human Genetics (2014) 22, doi:10.1038/ejhg.2013.156; published online 31 July 2013 Update to: European Journal of Human Genetics (2011) 19, doi:10.1038/ejhg.2011.32; published online 2 March 2011 1. DISEASE CHARACTERISTICS nonsense and missense mutations c.4333C4T (p.Arg1445*) and 1.1 Name of the disease (synonyms) c.4391A4C (p.His1464Pro), respectively, render CUL7 deficient 3-M syndrome (gloomy face syndrome, dolichospondylic dysplasia). in recruiting ROC1, leading to impaired ubiquitination. OBSL1: microsatellites analysis of the locus (2q35-36.1) in con- 1.2 OMIM# of the disease sanguineous families. OBSL1: microsatellites analysis of the locus 273750. (2q35-36.1) in consanguineous families. Mutations induce non- sense mediated decay. Knockdown of OBSL1 in HEK293 cells 1.3 Name of the analysed genes or DNA/chromosome segments shows the role of this gene in the maintenance of normal levels of CUL7, OBSL1 and CCDC8.1–5 CUL7. Abnormal IGFBP2 andIGFBP5 mRNA levels in two patients with OBSL1 mutations, suggesting that OBSL1 modulates the 1.4 OMIM# of the gene(s) expression of IGFBP proteins. CCDC8: microsatellites analysis 609577 (CUL7), 610991 (OBSL1) and 614145 (CCDC8). at the locus (19q13.2-q13.32). CCDC8, 1-BP DUP, 612G and CCDC8, 1-BP. -
Investigation of Modifier Genes Within Copy Number Variations in Rett Syndrome
See discussions, stats, and author profiles for this publication at: http://www.researchgate.net/publication/51147767 Investigation of modifier genes within copy number variations in Rett syndrome ARTICLE in JOURNAL OF HUMAN GENETICS · MAY 2011 Impact Factor: 2.53 · DOI: 10.1038/jhg.2011.50 · Source: PubMed CITATIONS DOWNLOADS VIEWS 6 89 134 15 AUTHORS, INCLUDING: Dag H Yasui Maria Antonietta Mencarelli University of California, Davis Azienda Ospedaliera Universitaria Senese 30 PUBLICATIONS 1,674 CITATIONS 58 PUBLICATIONS 962 CITATIONS SEE PROFILE SEE PROFILE Francesca Mari Janine M Lasalle Università degli Studi di Siena University of California, Davis 81 PUBLICATIONS 1,658 CITATIONS 98 PUBLICATIONS 3,525 CITATIONS SEE PROFILE SEE PROFILE Available from: Janine M Lasalle Retrieved on: 22 July 2015 Europe PMC Funders Group Author Manuscript J Hum Genet. Author manuscript; available in PMC 2012 January 01. Published in final edited form as: J Hum Genet. 2011 July ; 56(7): 508–515. doi:10.1038/jhg.2011.50. Europe PMC Funders Author Manuscripts Investigation of modifier genes within copy number variations in Rett syndrome Rosangela Artuso1,*, Filomena Tiziana Papa1,*, Elisa Grillo1, Mafalda Mucciolo1, Dag H. Yasui2, Keith W. Dunaway2, Vittoria Disciglio1, Maria Antonietta Mencarelli1, Marzia Pollazzon1, Michele Zappella3, Giuseppe Hayek4, Francesca Mari1, Alessandra Renieri1, Janine M. LaSalle2, and Francesca Ariani1 1 Medical Genetics Section, Biotechnology Department, University of Siena, Italy 2 Medical Microbiology and Immunology, Genome Center, School of Medicine, University of California, Davis, CA, USA 3 Child Neuropsychiatry, Versilia Hospital, Viareggio, Italy 4 Infantile Neuropsychiatry, Siena General Hospital, Italy Abstract MECP2 mutations are responsible for two different phenotypes in females, classical Rett syndrome and the milder Zappella variant (Z-RTT). -
Cytokine Nomenclature
RayBiotech, Inc. The protein array pioneer company Cytokine Nomenclature Cytokine Name Official Full Name Genbank Related Names Symbol 4-1BB TNFRSF Tumor necrosis factor NP_001552 CD137, ILA, 4-1BB ligand receptor 9 receptor superfamily .2. member 9 6Ckine CCL21 6-Cysteine Chemokine NM_002989 Small-inducible cytokine A21, Beta chemokine exodus-2, Secondary lymphoid-tissue chemokine, SLC, SCYA21 ACE ACE Angiotensin-converting NP_000780 CD143, DCP, DCP1 enzyme .1. NP_690043 .1. ACE-2 ACE2 Angiotensin-converting NP_068576 ACE-related carboxypeptidase, enzyme 2 .1 Angiotensin-converting enzyme homolog ACTH ACTH Adrenocorticotropic NP_000930 POMC, Pro-opiomelanocortin, hormone .1. Corticotropin-lipotropin, NPP, NP_001030 Melanotropin gamma, Gamma- 333.1 MSH, Potential peptide, Corticotropin, Melanotropin alpha, Alpha-MSH, Corticotropin-like intermediary peptide, CLIP, Lipotropin beta, Beta-LPH, Lipotropin gamma, Gamma-LPH, Melanotropin beta, Beta-MSH, Beta-endorphin, Met-enkephalin ACTHR ACTHR Adrenocorticotropic NP_000520 Melanocortin receptor 2, MC2-R hormone receptor .1 Activin A INHBA Activin A NM_002192 Activin beta-A chain, Erythroid differentiation protein, EDF, INHBA Activin B INHBB Activin B NM_002193 Inhibin beta B chain, Activin beta-B chain Activin C INHBC Activin C NM005538 Inhibin, beta C Activin RIA ACVR1 Activin receptor type-1 NM_001105 Activin receptor type I, ACTR-I, Serine/threonine-protein kinase receptor R1, SKR1, Activin receptor-like kinase 2, ALK-2, TGF-B superfamily receptor type I, TSR-I, ACVRLK2 Activin RIB ACVR1B -
High Throughput Circrna Sequencing Analysis Reveals Novel Insights Into
Xiong et al. Cell Death and Disease (2019) 10:658 https://doi.org/10.1038/s41419-019-1890-9 Cell Death & Disease ARTICLE Open Access High throughput circRNA sequencing analysis reveals novel insights into the mechanism of nitidine chloride against hepatocellular carcinoma Dan-dan Xiong1, Zhen-bo Feng1, Ze-feng Lai2,YueQin2, Li-min Liu3,Hao-xuanFu2, Rong-quan He4,Hua-yuWu5, Yi-wu Dang1, Gang Chen 1 and Dian-zhong Luo1 Abstract Nitidine chloride (NC) has been demonstrated to have an anticancer effect in hepatocellular carcinoma (HCC). However, the mechanism of action of NC against HCC remains largely unclear. In this study, three pairs of NC-treated and NC-untreated HCC xenograft tumour tissues were collected for circRNA sequencing analysis. In total, 297 circRNAs were differently expressed between the two groups, with 188 upregulated and 109 downregulated, among which hsa_circ_0088364 and hsa_circ_0090049 were validated by real-time quantitative polymerase chain reaction. The in vitro experiments showed that the two circRNAs inhibited the malignant biological behaviour of HCC, suggesting that they may play important roles in the development of HCC. To elucidate whether the two circRNAs function as “miRNA sponges” in HCC, we identified circRNA-miRNA and miRNA-mRNA interactions by using the CircInteractome and miRwalk, respectively. Subsequently, 857 miRNA-associated differently expressed genes in HCC were selected for weighted gene co-expression network analysis. Module Eigengene turquoise with 423 genes was found to be significantly related to the survival time, pathology grade and TNM stage of HCC patients. Gene functional enrichment 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; analysis showed that the 423 genes mainly functioned in DNA replication- and cell cycle-related biological processes and signalling cascades. -
Identification and Validation of Methylation-Driven Genes Prognostic Signature for Recurrence of Laryngeal Squamous Cell Carcino
Cui et al. Cancer Cell Int (2020) 20:472 https://doi.org/10.1186/s12935-020-01567-3 Cancer Cell International PRIMARY RESEARCH Open Access Identifcation and validation of methylation-driven genes prognostic signature for recurrence of laryngeal squamous cell carcinoma by integrated bioinformatics analysis Jie Cui3†, Liping Wang2†, Waisheng Zhong4†, Zhen Chen5, Jie Chen4*, Hong Yang3* and Genglong Liu1* Abstract Background: Recurrence remains a major obstacle to long-term survival of laryngeal squamous cell carcinoma (LSCC). We conducted a genome-wide integrated analysis of methylation and the transcriptome to establish methyla- tion-driven genes prognostic signature (MDGPS) to precisely predict recurrence probability and optimize therapeutic strategies for LSCC. Methods: LSCC DNA methylation datasets and RNA sequencing (RNA-seq) dataset were acquired from the Cancer Genome Atlas (TCGA). MethylMix was applied to detect DNA methylation-driven genes (MDGs). By univariate and multivariate Cox regression analyses, fve genes of DNA MDGs was developed a recurrence-free survival (RFS)-related MDGPS. The predictive accuracy and clinical value of the MDGPS were evaluated by receiver operating characteristic (ROC) and decision curve analysis (DCA), and compared with TNM stage system. Additionally, prognostic value of MDGPS was validated by external Gene Expression Omnibus (GEO) database. According to 5 MDGs, the candidate small molecules for LSCC were screen out by the CMap database. To strengthen the bioinformatics analysis results, 30 pairs of clinical samples were evaluated by digoxigenin-labeled chromogenic in situ hybridization (CISH). Results: A total of 88 DNA MDGs were identifed, and fve RFS-related MDGs (LINC01354, CCDC8, PHYHD1, MAGEB2 and ZNF732) were chosen to construct a MDGPS. -
Functional Characterization of BC039389-GATM and KLK4
Pflueger et al. BMC Genomics (2015) 16:247 DOI 10.1186/s12864-015-1446-z RESEARCH ARTICLE Open Access Functional characterization of BC039389-GATM and KLK4-KRSP1 chimeric read-through transcripts which are up-regulated in renal cell cancer Dorothee Pflueger1,2, Christiane Mittmann1, Silvia Dehler3, Mark A Rubin4,5, Holger Moch1,2 and Peter Schraml1* Abstract Background: Chimeric read-through RNAs are transcripts originating from two directly adjacent genes (<10 kb) on the same DNA strand. Although they are found in next-generation whole transcriptome sequencing (RNA-Seq) data on a regular basis, investigating them further has usually been refrained from. Therefore, their expression patterns or functions in general, and in oncogenesis in particular, are poorly understood. Results: We used paired-end RNA-Seq and a specifically designed computational data analysis pipeline (FusionSeq) to nominate read-through events in a small discovery set of renal cell carcinomas (RCC) and confirmed them in a larger validation cohort. 324 read-through events were called overall; 22/27 (81%) selected nominees passed validation with conventional PCR and were sequenced at the junction region. We frequently identified various isoforms of a given read-through event. 2/22 read-throughs were up-regulated: BC039389-GATM was higher expressed in RCC compared to benign adjacent kidney; KLK4-KRSP1 was expressed in 46/169 (27%) RCCs, but rarely in normal tissue. KLK4-KRSP1 expression was associated with worse clinical outcome in the patient cohort. In cell lines, both read-throughs influenced molecular mechanisms (i.e. target gene expression or migration/invasion) in a way that counteracted the effect of the respective parent transcript GATM or KLK4. -
Molecular Targeted and Immune Checkpoint Therapy for Advanced
Liu et al. Journal of Experimental & Clinical Cancer Research (2019) 38:447 https://doi.org/10.1186/s13046-019-1412-8 REVIEW Open Access Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma Ziyu Liu1†, Yan Lin2†, Jinyan Zhang2, Yumei Zhang2, Yongqiang Li2, Zhihui Liu2, Qian Li2, Ming Luo2, Rong Liang2* and Jiazhou Ye3* Abstract Molecular targeted therapy for advanced hepatocellular carcinoma (HCC) has changed markedly. Although sorafenib was used in clinical practice as the first molecular targeted agent in 2007, the SHARPE and Asian-Pacific trials demonstrated that sorafenib only improved overall survival (OS) by approximately 3 months in patients with advanced HCC compared with placebo. Molecular targeted agents were developed during the 10-year period from 2007 to 2016, but every test of these agents from phase II or phase III clinical trial failed due to a low response rate and high toxicity. In the 2 years after, 2017 through 2018, four successful novel drugs emerged from clinical trials for clinical use. As recommended by updated Barcelona Clinical Liver cancer (BCLC) treatment algorithms, lenvatinib is now feasible as an alternative to sorafenib as a first-line treatment for advanced HCC. Regorafenib, cabozantinib, and ramucirumab are appropriate supplements for sorafenib as second-line treatment for patients with advanced HCC who are resistant, show progression or do not tolerate sorafenib. In addition, with promising outcomes in phase II trials, immune PD-1/PD-L1 checkpoint inhibitors nivolumab and pembrolizumab have been applied for HCC treatment. Despite phase III trials for nivolumab and pembrolizumab, the primary endpoints of improved OS were not statistically significant, immune PD-1/PD-L1 checkpoint therapy remains to be further investigated. -
Mapping of Quantitative Trait Loci for Milk Yield Traits on Bovine Chromosome 5 in the Fleckvieh Cattle
From the Department of Veterinary Sciences Faculty of Veterinary Medicine Ludwig-Maximilians-Universität München Arbeit angefertigt unter der Leitung von Univ. Prof. Dr. Dr. habil. Martin Förster Mapping of Quantitative Trait Loci for Milk Yield Traits on Bovine Chromosome 5 in the Fleckvieh Cattle Inaugural–Dissertation For the attainment of Doctor Degree in Veterinary Medicine From the Faculty of Veterinary Medicine of the Ludwig-Maximilians-Universität München by Ashraf Fathy Said Awad from Sharkia- Egypt München 2011 Gedruckt mit Genehmigung der Tierärztlichen Fakultät der Ludwig–Maximilians–Universität München Dekan: Univ. Prof. Dr. Braun Berichterstatter: Univ. Prof. Dr. Dr. habil Förster Korreferent: Univ. Prof. Dr. Mansfeld Tag der Promotion: 12. February 2011 This work is dedicated to My Parents, my wife and my lovely daughters; Sama, Shaza, Hana CONTENTS CONTENTS ABBREVIATION……………………………………………………………… IV CHAPTER 1: GENERAL INTRODUCTION……………………………….. 1 CHAPTER 2: REVIEW OF LITERATURE………………………………… 3 2.1. DNA Markers……………………………………………………….. 3 2.1.1. Microsatellites………………………………………………………….. 3 2.1.2. Single Nucleotide Polymorphism (SNPs)…………………………… 4 2.2. Mapping of Quantitative Trait Loci (QTL)…………………….. 5 2.2.1. QTL Mapping Designs………………………………………………... 6 2.2.1.1. Daughter Design………………………………………………... 6 2.2.1.2. Granddaughter Design………………………………………… 7 2.2.1.3. Complex Pedigree Design…………………………………….. 9 2.2.2. QTL Mapping Strategies……………………………………………… 10 2.2.2.1. Candidate Gene Approach……………………………………. 10 2.2.2.2. Genome Scan Approach……………………………………… 11 2.3. Principles of Linkage Mapping…………………………………. 12 2.4. QTL Fine Mapping………………………………………………… 14 2.4.1. Linkage Disequilibrium……………………………………………… 15 2.4.2. Combined Linkage Disequilibrium and Linkage (LDL) Mapping… 17 2.5. Identification of Candidate Genes……………………………… 18 2.6. -
Characterization of the Lung Seven Transmembrane Recptor Protein
Florida State University Libraries Electronic Theses, Treatises and Dissertations The Graduate School 2012 Characterization of the Lung Seven Transmembrane (LUSTR) Protein Family Jennifer Ivey Middlebrooks Follow this and additional works at the FSU Digital Library. For more information, please contact [email protected] THE FLORIDA STATE UNIVERSITY COLLEGE OF ARTS AND SCIENCES CHARACTERIZATION OF THE LUNG SEVEN TRANSMEMBRANE (LUSTR) PROTEIN FAMILY By JENNIFER IVEY MIDDLEBROOKS A Dissertation submitted to the Department of Biological Sciences in partial fulfillment of the requirements for the degree of Doctor of Philosophy Degree Awarded: Summer Semester, 2012 Jennifer Ivey Middlebrooks defended this dissertation on June 1, 2012. The members of the supervisory committee were: Laura R. Keller Professor Directing Dissertation Cathy Levenson University Representative Tom Keller Committee Member Karen McGinnis Committee Member Wumin Deng Committee Member The Graduate School has verified and approved the above-named committee members, and certifies that the dissertation has been approved in accordance with university requirements. ii This work is dedicated to my loving, supportive family. iii ACKNOWLEDGEMENTS We thank Dr. Kenneth Roux and Leanna Willison (FSU Biological Science Dept.) for technical advice and reagents for completion of the immunoblot analysis, Dr. Tim MeGraw (FSU College of Medicine) for the use of his reagents and equipment for the immunofluorescent imaging, Dr. Gavin J.P. Naylor (College of Charleston) and Dr. Steven M. Thompson (South Georgia College) for their instruction and advice on the bioinformatic and phylogenetic analysis, and we acknowledge the Florida State University shared High-Performance Computing facility for facilitating the bioinformatic analyses. Additionally, we thank Dr. Joan Hare for her direction with human cell culture, Cody DeBrabaunt for his assistance in cell staining and microscopy, and Dr. -
Supplemental Information
Supplemental information Dissection of the genomic structure of the miR-183/96/182 gene. Previously, we showed that the miR-183/96/182 cluster is an intergenic miRNA cluster, located in a ~60-kb interval between the genes encoding nuclear respiratory factor-1 (Nrf1) and ubiquitin-conjugating enzyme E2H (Ube2h) on mouse chr6qA3.3 (1). To start to uncover the genomic structure of the miR- 183/96/182 gene, we first studied genomic features around miR-183/96/182 in the UCSC genome browser (http://genome.UCSC.edu/), and identified two CpG islands 3.4-6.5 kb 5’ of pre-miR-183, the most 5’ miRNA of the cluster (Fig. 1A; Fig. S1 and Seq. S1). A cDNA clone, AK044220, located at 3.2-4.6 kb 5’ to pre-miR-183, encompasses the second CpG island (Fig. 1A; Fig. S1). We hypothesized that this cDNA clone was derived from 5’ exon(s) of the primary transcript of the miR-183/96/182 gene, as CpG islands are often associated with promoters (2). Supporting this hypothesis, multiple expressed sequences detected by gene-trap clones, including clone D016D06 (3, 4), were co-localized with the cDNA clone AK044220 (Fig. 1A; Fig. S1). Clone D016D06, deposited by the German GeneTrap Consortium (GGTC) (http://tikus.gsf.de) (3, 4), was derived from insertion of a retroviral construct, rFlpROSAβgeo in 129S2 ES cells (Fig. 1A and C). The rFlpROSAβgeo construct carries a promoterless reporter gene, the β−geo cassette - an in-frame fusion of the β-galactosidase and neomycin resistance (Neor) gene (5), with a splicing acceptor (SA) immediately upstream, and a polyA signal downstream of the β−geo cassette (Fig. -
New Insights Into the Functional Mechanisms and Clinical Applications of the Kallikrein-Related Peptidase Family
MOLECULAR ONCOLOGY 1 (2007) 269–287 available at www.sciencedirect.com www.elsevier.com/locate/molonc Review New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family Nashmil Emamia,b, Eleftherios P. Diamandisa,b,* aDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M5G 1L5, Canada bDepartment of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada ABSTRACT ARTICLE INFO Article history: The Kallikrein-related peptidase (KLK) family consists of fifteen conserved serine proteases Received 13 July 2007 that form the largest contiguous cluster of proteases in the human genome. While primar- Received in revised form ily recognized for their clinical utilities as potential disease biomarkers, new compelling 4 September 2007 evidence suggests that this family plays a significant role in various physiological pro- Accepted 7 September 2007 cesses, including skin desquamation, semen liquefaction, neural plasticity, and body fluid Available online 15 September 2007 homeostasis. KLK activation is believed to be mediated through highly organized proteo- lytic cascades, regulated through a series of feedback loops, inhibitors, auto-degradation Keywords: and internal cleavages. Gene expression is mainly hormone-dependent, even though tran- Kallikrein-related peptidases scriptional epigenetic regulation has also been reported. These regulatory mechanisms are PSA integrated with various signaling pathways to mediate multiple functions. Dysregulation of Proteolytic cascades these pathways has been implicated in a large number of neoplastic and non-neoplastic Skin desquamation pathological conditions. This review highlights our current knowledge of structural/ * Corresponding author. Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada. -
Free PDF Download
Eur opean Rev iew for Med ical and Pharmacol ogical Sci ences 2013; 17: 2318-2322 Molecular changes of mesenchymal stromal cells in response to dexamethasone treatment J.- M. CHEN, X.-P. CUI 1, X.-D. YAO, L .-H. HUANG, H. XU Department of Orthopedics, Fuzhou General Hospital of Nanjing Command, PLA, Clinical Medical College of Fujian Medical University, Fuzhou, People’s Republic of China 1Department of Neurology, Fuzhou General Hospital of Nanjing Command, PLA Clinical Medical College of Fujian Medical University, Fuzhou, People’s Republic of China Jian-Mei Chen and Xiao-Ping Cui should be regarded as co-first authors Abstract. – BACKGROUND: Mesenchymal stem such as repair of impairment of bone, cartilage, cells (MSCs) are multipotent stromal cells that can tendons and other tissues 3. Research on the MSCs differentiate into a variety of cell types. The MSCs culture, proliferation and differentiation under canAbIMe a: ctivated and mobilized if needed. This study aimed to investigate the re - regulation was critical . sponse mechanism of MSCs under Dexametha - Dexamethasone (Dex) is a potent synthetic sone (Dex) treatment by combining MSCs mi - member of the glucocorticoid class of steroid drugs croMarAraTyERaInAdLbSioAiNnfDorMmaEtTicHsOmDSet:hods. that has immunosuppressant and anti-inflammato - We downloaded ry properties 4. It has been widely used as anti-in - the gene expression profile of ratʼs MSCs chal - flammatory and chemotherapeutic agents 5; howev - lenge with or without Dex (GSE3339) from Gene Expression Omnibus database, including 2 Dex er, prolonged use of Dex enhances direct respon - treated samples and 3 untreated samples. The dif - siveness of osteoblasts and ultimately impairs bone ferentially expressed genes (DEGs) were identi - formation, leading to changes in cell number and fied by packages in R language.